Efficacy of 3 years of adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance

Table 3 Response to adefovir salvage therapy n (%)

Project		HBV DNA (copies/mL)			HBeAg positive		rtA181V/S variation
		103	103-106	≥107	HBeAg seroconversion	HBeAg elimination	Change drug
Baseline level	A	12 (23.0)	22 (42.43)	18 (34.6)	36
	B	5 (20.8)	11 (45.8)	8 (33.3)	17
12 wk	A	30 (57.7)1	18 (34.6)	4 (7.6)2	0 (0)	2 (5.5)
	B	14 (58.3)4	8 (33.3)	2 (8.3)5	1 (5.8)	1 (5.8)
24 wk	A	32 (61.5)4	20 (38.4)	0 (0)3	4 (11.1)	2 (5.5)	2 (5.5)
	B	15 (62.5)4	8 (33.3)	1 (4.1)5	2 (11.7)	2 (11.7)	1 (5.8)
52 wk	A	34 (65.4)1	18 (34.6)	0 (0)3	4 (11.1)	2 (5.5)	2 (5.5)
	B	16 (66.6)4	8 (33.3)	0 (0)5	4 (23.5)	2 (11.7)	1 (5.8)
104 wk	A	36 (69.2)1	16 (30.7)	0 (0)3	8 (22.2)	4 (11.1)	2 (5.5)
	B	16 (66.6)4	8 (33.3)	0 (0)5	4 (23.5)	2 (11.7)	1 (5.8)
156 wk	A	34 (65.4)1	16 (30.7)	2 (3.8)3	8 (22.2)	6 (16.6)	4 (11.1)
	B	15 (62.5)4	8 (33.3)	1 (4.1)5	4 (23.5)	2 (11.7)	2 (11.7)

Group A: Treated with adefovir; Group B: Treated with adefovir and lamivudine;

¹P < 0.001 (χ² = 6.4-11.0) vs group A baseline HBV DNA 10³ copies/mL;

²P < 0.05 (χ² = 4.7);

³P < 0.01 (χ² = 7.9-10.8) vs group A baseline HBV DNA 10⁷ copies/mL;

⁴P < 0.001 (χ² = 5.9-11.7) vs group B baseline HBV DNA 10³ copies/mL;

⁵P < 0.01 (χ² = 7.7-11.0) vs group B baseline HBV DNA 10⁶ copies/mL. HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen.